Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

POM Wonderful has developed and patented a form of polyphenol antioxidants from pomegranate that is "so concentrated that only a small amount is needed to obtain an optimal level of daily antioxidants," according to the Los Angeles, Calif.-based firm. "For consumers who are not seeking additional calories and sugars, this is an important product benefit." POMx currently is available to consumers as the active ingredient in POM Tea, which launched in May. At this time, POM Wonderful has no plans to offer the compound in non-beverage products, according to a spokesperson. The announcement of the ingredient's availability follows the publication of several recent studies on the health benefits of pomegranates, including a July 1 Clinical Cancer Research study finding that a daily regime of POM Wonderful juice prolonged prostate-specific antigen (PSA) doubling time from 15 to 54 months. The study was supported by a grant from the firm...

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts